From cornflakes to the pacemaker, some of our most beloved—and useful—products were born of blunders. https://t.co/9MvXAzx1fp ...

Summary of Orchestra BioMed FY Conference Call (March 03, 2026) Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Development of innovative medical technologies, particularly in the fields of hypertension and coronary artery disease through partnerships with established companies like Medtronic and Terumo [1][2] Key Programs and Developments AVIM Therapy - **Indications**: Targets hypertensive heart disease and coronary artery disease, utilizing a pacemaker for delivery [3][4] - **Market Opportunity**: Estimated over $17 billion annual global opportunity in treating hypertension within the pacemaker population [5] - **Clinical Trials**: Actively enrolling in the BACKBEAT pivotal trial for AVIM therapy, with a goal to complete enrollment in 2026 and data readout expected in 2028 [4][24] - **Mechanism**: AVIM therapy modulates blood pressure by shortening the timing of atrial and ventricular contractions, leading to immediate and sustained blood pressure reduction [16][17] - **Clinical Data**: Demonstrated significant reductions in systolic blood pressure (average drop of 15.5 mmHg) and improvements in diastolic function in patients with isolated systolic hypertension [20][22] VIRTUE Sirolimus AngioInfusion Balloon - **Product Description**: A first-of-its-kind non-coated drug-eluting balloon designed for coronary artery disease treatment, leveraging a proprietary sirolimus formulation [25][26] - **Market Shift**: The market is transitioning from permanent implants like stents to drug-coated balloons, with a significant opportunity in both coronary and peripheral artery disease [25][26] - **Clinical Trials**: Enrolling patients in a pivotal trial against Boston Scientific's AGENT balloon, aiming for non-inferiority and potential superiority [30][44] - **Performance Metrics**: Achieved a low target lesion failure rate of 2.8% at one year, indicating strong clinical outcomes [29] Financial Position - **Funding**: Well-capitalized through late 2027, with recent transactions bringing in additional capital, including $21 million from the sale of Vivasure and $35 million in tranche payments from partnerships [7][8] - **Royalty Structure**: Potential royalties of $500 to $1,600 per device sold by Medtronic, with significant revenue opportunities anticipated from AVIM therapy [14][15] Strategic Partnerships - **Medtronic**: A key partner, holding over 50% of the global pacing market, with exclusive rights to commercialize devices incorporating AVIM therapy [15][16] - **Terumo**: Holds a right of first refusal for the VIRTUE product, with a recent investment of $65 million [30][31] Market Trends and Insights - **Hypertension and Heart Failure**: Elevated systolic blood pressure is a major driver of heart failure progression, with AVIM therapy positioned as a preventive treatment for patients at risk [34][35] - **Drug-Eluting Balloon Market**: Increasing adoption of drug-coated balloons in coronary procedures, particularly in Europe and Asia, with a growing recognition of the need for differentiated products [41][42] Conclusion - **Outlook**: 2026 is positioned as a pivotal year for Orchestra BioMed, with significant clinical trials underway and a strong financial foundation to support growth and innovation in the medical device sector [31][32]

Now to MSNOW'S ALEX TABBETT, WHO JUST SPOKE WITH THE PIMA COUNTY SHERIFF ABOUT NANCY GUTHRIE'S DISAPPEARANCE. ALEX, WHAT DID THE SHERIFF TELL YOU. WELL, LAURA, I ASKED THE SHERIFF ABOUT THE TECHNOLOGY THAT'S BEING USED IN THIS CASE AND HE, HE IDENTIFIED THREE MAIN FOCUSES OF THE ADVANTAGATION.I WANT YOU TO HEAR WHAT HE HAD TO SAY. CAN YOU TALK TO ME ABOUT HOW TECHNOLOGY IS PLAYING A ROLE. WE'VE BEEN HEARING REPORTS OF SIGNAL SNIFFERS.WHAT TYPES OF technology are you using in this investigation right now. So ...